SCHEMBL17189791

SCHEMBL17189791

COc1ccc(-n2c(SCCCN3C(=O)c4cccc5cccc(c45)C3=O)nnc2-c2ccncc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS2 Q9H2K2 7/20 1.00
▸ ALDH1A1 P00352 4/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ HTR1A P08908 1/20 0.52
▸ DRD2 P14416 1/20 0.52
▸ HTR2A P28223 1/20 0.52
▸ HTR6 P50406 1/20 0.52
▸ TNKS O95271 4/20 0.50
▸ MAPT P10636 4/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ THRB P10828 1/20 0.50
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ HPGD P15428 1/20 0.48
▸ TP53 P04637 2/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ SULT2A1 Q06520 1/20 0.48
▸ NR5A1 Q13285 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29495940 1.00 TNKS2 (1.00) TNKS2ALDH1A1KDM4EHTR1ADRD2
SCHEMBL21816546 0.83 TNKS2 (0.71) TNKS2ALDH1A1TNKSMAPTSMN1; SMN2
SCHEMBL16486612 0.81 TNKS2 (0.67) TNKS2ALDH1A1MAPTHPGDCYP3A4
SCHEMBL11919933 0.72 ALDH1A1 (0.58) TNKS2ALDH1A1TNKSMAPTSMN1; SMN2
SCHEMBL6403463 0.72 CYP3A4 (0.73) TNKS2ALDH1A1TNKSMAPTSMN1; SMN2
SCHEMBL11919912 0.71 TNKS2 (0.58) TNKS2ALDH1A1TNKSMAPTSMN1; SMN2
SCHEMBL6192012 0.70 ALPG (0.69) TNKS2ALDH1A1KDM4ETNKSMAPT
SCHEMBL27242770 0.68 TNKS2 (0.52) TNKS2ALDH1A1KDM4EHTR1ADRD2
SCHEMBL6193193 0.68 CDC25A (0.74) ALDH1A1MAPTTHRBMEN1KMT2A
SCHEMBL6192401 0.68 ALPG (0.74) TNKS2ALDH1A1KDM4ETNKSMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110564677-B Inducer for inducing pluripotent stem cells to differentiate into beating cardiac muscle cells and application thereof 上海泉生生物科技有限公司 2022-09-09 — — CN claimed
WO-2020068665-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN FABIUS BIOTECHNOLOGY (US) 2020-04-02 — — WO claimed
US-10064862-B2 Antiviral axin stabilizer THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) 2018-09-04 — — US claimed
US-20170065587-A1 ANTIVIRAL AXIN STABLIZER THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY 2017-03-09 — — US claimed
WO-2024113351-A1 CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) 2024-06-06 — — WO disclosed
WO-2024113354-A1 CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) 2024-06-06 — — WO disclosed
WO-2024101385-A1 METHOD FOR PRODUCING PLURIPOTENT STEM CELLS AND METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS 株式会社カネカ 2024-05-16 — — WO disclosed
WO-2024048555-A1 COMBINATION DRUG 中外製薬株式会社 2024-03-07 — — WO disclosed
WO-2023149495-A1 PRODUCTION METHOD FOR INDUCED PLURIPOTENT STEM CELLS 国立研究開発法人理化学研究所 2023-08-10 — — WO disclosed
US-20230203447-A1 Methods of Producing Specialized Cardio-Like Cells from Stem Cells UNIV EMORY (US) 2023-06-29 — — US disclosed
WO-2023017806-A1 METHOD FOR PRODUCING PLURIPOTENT STEM CELLS 株式会社カネカ 2023-02-16 — — WO disclosed
EP-4105319-A1 METHOD FOR SUPPRESSING DIFFERENTIATION OF PLURIPOTENT STEM CELLS Kaneka Corporation (JP) 2022-12-21 — — EP disclosed
WO-2021162090-A1 METHOD FOR SUPPRESSING DIFFERENTIATION OF PLURIPOTENT STEM CELLS 株式会社カネカ 2021-08-19 — — WO disclosed
US-10624949-B1 Methods for treating diseases related to the wnt pathway NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) 2020-04-21 — — US disclosed
CN-110564677-A inducer for inducing pluripotent stem cells to differentiate into beating cardiomyocytes and application thereof 杭州标模生物科技有限公司 2019-12-13 — — CN disclosed
US-20190136191-A1 Methods of Producing Specialized Cardio-Like Cells from Stem Cells EMORY UNIVERSITY 2019-05-09 — — US disclosed
US-10064862-B2 Antiviral axin stabilizer THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) 2018-09-04 — — US disclosed
US-20170065587-A1 ANTIVIRAL AXIN STABLIZER THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY 2017-03-09 — — US disclosed
US-20150301067-A1 METHODS AND ASSAYS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2015-10-22 — — US disclosed
US-20150301067-A1 METHODS AND ASSAYS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2015-10-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10064862-B2 Antiviral axin stabilizer IRF3, AXIN2, TANK TNKS2 10/4885ALDH1A1 2456/4885KDM4E 2840/4885
US-20170065587-A1 ANTIVIRAL AXIN STABLIZER TNKS1BP1, TNKS, TANK TNKS2 7/4885ALDH1A1 1947/4885KDM4E 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback